Ozempic is in the next round of medicine Drug Price Negotiations. See the full list of 15 medicines

The biden administration on Friday unveiled the Next 15 prescription drugs That will be subject to price Negotiations Between manufacturers and medicine, kicking off the second phase of a landmark process That aims to make costly medicines more affordable for seniors.

Topping the list are Novo Nordisk‘S Blockbuster Diabetes Injection OzEMPIC, Weight Loss Shot Wegovy and Diabetes Pill Rybelsus, which are considered one product in the talksSince they all share the same active ingredient: semaglutide. Thos treatment fuled the risk of the red-hit obesity Drug Market and Have ben Difential for Patients to access due to cost, Insurance Coverage and Supply Constrants.

The agreed-upon prices for the second wave of Drugs are Scheduled to Go INTO EFFECT In 2027. En he takes office next week.

Here are the 15 Drugs Subject to the Initial Talks This Year:

• Ozempic, wegovy, rybelsus, (semaglutide) Made by Novo Nordisk, is used for type 2 diabetes, weight management, and cardiovascular health
• Trelegy Ellipta, Made by GskIs an inhaler used for chronic obstructive pulmonary disease and asthma
• Xtandi, Made by Pfizer And astellas pharma, is used to treat prostate cancer in men
• Pomalyst, Made by Bristol Myers SquibbIs used to treat a blood cancer called multiple myeloma and a cancer that develops in people with hiv
• Ibrance, Made by pfizer, is used to treatment breast cancers
• Ofev, Made by Boehringer inglheim, is used to treat chronic lung diseases in adults.
• Linzess, Made by Abbvie and Ironwood pharmaceuticalsIs used to treat irritable bowel syndrome and chronic constipation
• Calquence, Made by AstraznecaIs used to treatment types of blood cancer
• Austedo, Austedo XR, Made by Teva pharmaceuticalsIs used to treat involuntary movements caused by Tardive dyskinesia or huntington’s disease
• Breo Ellipta, Made by gsk and TheravanceIs an inhaler used to treat chronic obstructive pulmonary disease
• Tradjenta, Made by Boehringer inglheim and Eli lillyIs used for type 2 diabetes management
• Xifaxan, Made by salix pharmaceuticals, is used to treat diarrhea caused by traveling or irritable bowel syndrome
• Vraylar, Made by abbvie, is used to treat schizophrenia, bipolar I disorder, and major depressive disorder
• Janumet, Janumet XR, Made by MerckIs used to manage type 2 diabetes
• Otezla, Made by AmgenIs used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers

President Joe Biden’s Inflation Reduction Act Gave Medicare The Power to Directly Hash out Drug Prisies with Manufacturers for the First Time in the Federal Program’s Nearly 60-Eera History. Some congressional democrats and consumer advocates have long pushed for the change, as many seniors Around the country struggle to afford care.

Medicare has alredy completes for the first 10 drugs selected in the program, with new prices set to go into effect next year. In August, The biden administration said it expects that that negotiated prices to save medicine Around $ 1.5 billion in out-of-pocket costs in 2026 alone. The government also expects the pris to lead $ 6 billion in nets for the medicine program in 2026Or 22% net saveings overall.

In an interview, centers for medicine & medicine services Administrator Chique Brooks-Lascar Said The Biden Administration Carried Out The Law As Written and Added, “I HOPEE THET THET THET THET THET THET THET THET THET THE TETE THE SAME SAME She added that any revisions to the negotiation process would require Congress to change the law.

CMS Announced the list more than two weeks before a Feb. 1 deadline to do so. Brooks-Lassure Said That Timing Gives Companies, PATIENT Groups, Academics and Other Stakeholders more “Time to know they are on the list and real start getting prepared to make the decision to move.”

The Negotiation Period Ends in November, which “sounds like a long time but takes a number of steps,” She said.

About 5.3 Million People with Medicare Part D Coverage Used The 15 Drugs On the Second-RED LIST to Treat Various Various Conditions, Such as AS ASTHMA, Cancer and Type 2 Diabetes, Between Nov. 1, 2023, and Oct. 31, 2024, according to a release from the department of health and human services on Friday.

The group of medicines also accounted for roughly $ 41 billion, or 14%, of total part d prescription Drug Costs DURING that Time Period, the release added. When combined with the 10 medicines selected for the first cycle of negotiations, the 25 products representing 36% of all medicine part d prescription drug costs during the time, the release said.

The drugs have been on the market for at least seven years with generic competitors, or 11 years in the case of biological products such as vaccines.

The Negotiation program has decided a flurry of legal challenges, so far unsuccessful, from the pharmaceutical industry, which views the process the process as a thret to it is a threat to it.

Stephen UBL, The Industry’s Biggest Lobbying Group, Phrma, Said in a Statement Friday that Negotiations are “Danger for Millions of Americans of Americans who innovative Ostly Bureaucracy. “

“In rushing out this list in their final days, the biden administration once against fails to address the True Challenges Facing Seniors and Medicare,” He Added, Content That The Proce l form much earlier than other types of Medicine. Phrma is eager to work with the trump Administration and Congress to “Fix” that “that” Pill Penalty, “Ubl Said.

In a statement on friday, novo nordisk said it is opposed to the negotiations and has “significant concerns” about how the biden administration is implementing is implemented the law. The Danish Drugmaker Specifically Criticized The Decision to Combine Multiple Products that “Individually Delhi Not Meet The Requirements of the Statute,” Referring to Ozempic, Rybelsus and Youngovy Beeing List Roduct.

Novo Nordisk Said Its Lawsuit Against The Program is Still Pending, And It will work with the Trump Administration to Deliver “meaningful Solutions for PATINES.”

Medicare Covers Roughly 66 Million People in the US, and 50.5 Million Patients are currently enrolled in part d plans, according to health policy research organization kff.

Almost 10% of Medicare Enrollees Ages 65 and Older, and 20% of that that Under 65, Report Challenges in Affording Drugs, A Senior Administration Official Told Reports in 2024.

“Last Year We Proved That Negotiating for Lower Drug Prisis. ecerra said in a release Friday. “Today’s Announsment is Pivotal-The Inflation Reduction Act is Lowering Price for People on Medicare. ingles at lower costs. “

Patient Advocacy Groups, Such as Nonprofit aarp, applauded the announcing friday.

“For Too long, big drug companies have padded their rights by setting out the expensese of american lives, forcing seniors to skip prescriptions, they can’t Aford,” Advocacy and Engagement Officer, said in a statement. “The first round of medicine drug price negotiation

Among the 10 Drugs Listed, Medicare Part D Spent The Most On OzEmpic, Rybelsus and Wegovy, At $ 14.43 billion, according to a Fact Sheet Published friday by the centers for medicine & medicine services, or CMS. Nearly 2.3 Million Enrollees Used Theose Drugs Between Nov. 1, 2023, and Oct. 31, 2024, HHS said in a release.

Brooks-lacure said the inclusion of semaglutide may help people “to see how important it was for medicine to get to negotiate prescription drugs.”

The biden administration in late 2024 proposed allowing medicine and medicine to start covering wegovy and other obesity medicines for weight loss in particular. Brooks-Lassure Said She Hopes the Trump Administration Finalizes that Proposal.

She said it would mean medicine’s final negotiated price for semaglutide would apply to all of its branded products, Regardless of why they are prescribed. Medicare does not currently cover wegovy for weight loss, but does cover

The plan also spent roughly $ 5.14 billion on Trelegy Ellipta, which was used by 1.3 Million Enrollees. Xtandi Cost Medicare Part D $ 3.16 billion despite only 35,000 enrollles using the medicine, the fact Sheet Said.

Spending for pomalyst was $ 2.07 billion, and just 14,000 enrollees used that drug. All other drugs listed cost the program under $ 2 billion.

Medicare Part D Spent The Least on Otezla at $ 995 Million, with 31,000 enrollees who used that medicine, according to the fact sheet.

In Separate Statements, Bristol Myrs Squibb, Teva Pharmaceuticals and Boehringer inglheim argued that the price talks group paper

Bristol Myers Squibb Pointed to the Role of the Insurance Industry in High Health-Care Costs, Arguing that the Negotiations Overlook the “Biggest Problem in Patint Afordability: How Plans Pocket costs. “

Meanwhile, astrazneca said in a statement that it does not believe calquence is eligible for the program “as a result of recent innovations.” The company Urged CMS to Reconsider its selection of drugs.

Drugmakers will have until Feb. 28 to Decide Whether to Participate in the program. If a drugmaker declines to negotiate, it must either pay an excise tax of up to 95% of its medicine’s us sales or pull all of its products from the Medicare and Medicaid Markets.

That that participate will engage in a lengthy negotiation process involving months of back -and-forth price offers with medicine. The Federal Program Determines Its Initial Offer for Each Sales Volume Data, The Level of Federal Financial Support for the Drug’s Development and Data on PENDING or Among other information.

After the second round concludes, Medicare Can Negotiate Pries for Another 15 Drugs that will go into effect in 2028. The number rises to 20 negotiated medications a year starting in 2029.

The government will only select medicine part d drugs for the first two rounds of negotiations. It will add more specialized medicines covered by medicine part b, which are typical administerred by doctors, in 2028.

But drugmakers will have more opportunities to negotiate with medical, based on the Final guidance Released in October for the second round of price talks. The first optional negotiation meetings will take place after medicare makes its initial price offers for the 15 drugs, which must be presented by June 1,

“I think for the most part, we feel like a lot of the process work very well” Folling the first found of negotiations, brooks-lassure said. “I think some of the things that we want to containue to strengthen is helping outside stakeholders to know what kind of information is helpful for the team.”